A second tranche of up to $15 million will be available on or before December 31, 2016 if CytRx announces positive data from its global pivotal Phase 3 clinical trial of aldoxorubicin for the treatment of soft tissue sarcoma and initiates a clinical trial of a second novel drug candidate based on CytRx’s LADR technology platform. “This financing is an important step for CytRx as we complete our pivotal, global Phase 3 trial with aldoxorubicin and prepare for its commercial launch,” said Steven A. Kriegsman, Chairman and CEO. “We are pleased to team up with CytRx in advance of their results from the pivotal Phase 3 clinical trial. This financing will support CytRx through this key milestone and the future launch of aldoxorubicin,” said Anup Arora, Managing Director at Hercules Technology. The financing is in the form of a 48-month term loan bearing interest at a rate of https://boydppxs421.wordpress.com/2016/02/12/helpful-ideas-for-consideration-of-rational-programs-in-business-capital/ 9.5% per annum, subject to the variability of the prime interest rate. In the first year of the long-term loan, only interest is payable. If the regulatory milestone relating to data from the aldoxorubicin Phase 3 trial is positive, the interest-only period will be extended for an additional six months. If the second tranche of $15 million is funded to CytRx under the loan and security agreement, the interest-only period will be extended for another six months. In connection with the loan and security agreement, CytRx paid and issued to the lenders certain fees of approximately $450,000 and warrants to purchase approximately 630,000 shares of common stock of CytRx at an exercise price of $2.05 per share. Armentum Partners, through Trump Securities, LLC and Reedland Capital Partners, through Merriman Capital, Inc., a registered broker-dealer and member FINRA/SIPC, acted as financial advisors to CytRx in connection with the transaction. About CytRx Corporation CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. CytRx currently is focused on the clinical development of aldoxorubicin, its improved version of the widely used chemotherapeutic agent doxorubicin, and DK049, a novel drug conjugate which is expected to enter clinical trials in 2016. CytRx is also expanding its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx’s expertise in albumin biology and linker technology for the development of a new class of anti-cancer therapies. About Hercules Technology Growth Capital, Inc.
Something You And Only You Can Make Happen.
Many other companies advance cash to the car owners even with a bad credit history. Henry Ford once said “Whether you think you can or you can’t, you’re right”. My time in military service taught me one great life lesson. Once the car owner repays the loan, the company returns the title to the car. The second way they make there money is the interest only monthly payments on the loan which is anywhere from 10% to 14%. However, non-payment is always looked at as a breach in confidence. These loans are ideal for you, however, your being a defaulter or negative credit holder, does affect your loan approval process in several ways. What makes you different? This obviously goes down negatively and brings to you hesitant lenders and their stringent and inflexible terms and conditions.
To Be Eligible For These Loans, You Need To Pledge Some Valuable Asset As Collateral.
I recently attended a real estate investment seminar in La Vegas. What makes you different? These loans are ideal for you, however, you’re being a defaulter or negative credit holder, does affect your loan approval process in several ways. Know you can do it and get out there and do it. Options that will get their deals funded, and options that you, the expert commercial mortgage broker can offer. It will make your job easier in the long ladder. These loans offer you with a big advantage allowing you to get the car for drive even during the car title loan period.